Literature DB >> 12957811

Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria.

Bernd Hoppe1, Ernst Leumann, Gerd von Unruh, Norbert Laube, Albrecht Hesse.   

Abstract

Secondary hyperoxaluria is due either to increased intestinal oxalate absorption or to excessive dietary oxalate intake. Certain intestinal diseases like short bowel syndrome, chronic inflammatory bowel disease or cystic fibrosis and other malabsorption syndromes are known to increase the risk of secondary hyperoxaluria. Although the urinary oxalate excretion is usually lower than in primary hyperoxaluria, it may still lead to significant morbidity by recurrent urolithiasis or progressive nephrocalcinosis. A clear distinction between primary and secondary hyperoxalurias is important. As correct classification may be difficult, appropriate diagnostic tools are needed to delineate the metabolic background as a basis for optimal treatment. We developed an individual approach for the evaluation of patients with suspected secondary hyperoxaluria. First, 24 h urines are examined repeatedly for lithogenic (e.g. calcium, oxalate, uric acid) and stone-inhibitory (e.g. citrate, magnesium) substances, and the patients are asked to fill in a dietary survey form. Urinary saturation is calculated using the computer based program EQUIL2, and the BONN-Risk-index is determined. The measurement of plasma oxalate and of urinary glycolate helps to distinguish between primary and secondary hyperoxalurias. If secondary hyperoxaluria is suspected, the stool is examined for Oxalobacter formigenes, an intestinal oxalate degrading bacterium, as lack or absence may lead to increased intestinal oxalate absorption. The last diagnostic step is to study the intestinal oxalate absorption using [13C2]oxalate. Depending on the results, various therapeutic options are available: 1) a diet low in oxalate, but normal or high in calcium, 2) a high fluid intake (>1.5 L/m2/d), 3) medications to increase the urinary solubility, 4) specific therapeutic measures in patients with malabsorption syndromes, depending on the underlying pathology, and 5) intestinal recolonization of Oxalobacter formigenes or the treatment with other oxalate degrading bacteria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957811     DOI: 10.2741/1135

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  19 in total

1.  Genetically engineered Lactobacillus plantarum WCFS1 constitutively secreting heterologous oxalate decarboxylase and degrading oxalate under in vitro.

Authors:  Ponnusamy Sasikumar; Sivasamy Gomathi; Kolandaswamy Anbazhagan; A Ebenezer Baby; J Sangeetha; Govindan Sadasivam Selvam
Journal:  Curr Microbiol       Date:  2014-07-03       Impact factor: 2.188

Review 2.  Molecular therapy of primary hyperoxaluria.

Authors:  Cristina Martin-Higueras; Armando Torres; Eduardo Salido
Journal:  J Inherit Metab Dis       Date:  2017-04-19       Impact factor: 4.982

3.  Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease.

Authors:  Renate Hueppelshaeuser; Gerd E von Unruh; Sandra Habbig; Bodo B Beck; Stephan Buderus; Albrecht Hesse; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2012-02-25       Impact factor: 3.714

4.  Metabolic stress response patterns in urinary compositions of idiopathic calcium oxalate stone formers, patients with chronic bowel diseases and controls.

Authors:  Wolfgang Berg; Sabine Gayde; Christine Uhlemann; Norbert Laube
Journal:  Urol Res       Date:  2010-05-04

5.  Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.

Authors:  Heike Hoyer-Kuhn; Sina Kohbrok; Ruth Volland; Jeremy Franklin; Barbara Hero; Bodo B Beck; Bernd Hoppe
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-02       Impact factor: 8.237

6.  Risk factors associated to kidney stones in primary hyperparathyroidism.

Authors:  S Corbetta; A Baccarelli; A Aroldi; L Vicentini; G B Fogazzi; C Eller-Vainicher; C Ponticelli; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

Review 7.  Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?

Authors:  Bernd Hoppe; Gerd von Unruh; Norbert Laube; Albrecht Hesse; Harmeet Sidhu
Journal:  Urol Res       Date:  2005-11-13

8.  Urinary excretion of calcium, magnesium, phosphate, citrate, oxalate, and uric acid by healthy schoolchildren using a 12-h collection protocol.

Authors:  Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2014-08-31       Impact factor: 3.714

9.  A new approach to the diagnosis of children's urolithiasis based on the Bonn Risk Index.

Authors:  Tadeusz Porowski; Walentyna Zoch-Zwierz; Jerzy Konstantynowicz; Katarzyna Taranta-Janusz
Journal:  Pediatr Nephrol       Date:  2008-03-12       Impact factor: 3.714

Review 10.  Diagnostic examination of the child with urolithiasis or nephrocalcinosis.

Authors:  Bernd Hoppe; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2008-12-23       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.